Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 5;4(2):118-25.
doi: 10.1016/j.ijpddr.2014.03.002. eCollection 2014 Aug.

Idiosyncratic Quinoline Central Nervous System Toxicity: Historical Insights Into the Chronic Neurological Sequelae of Mefloquine

Affiliations
Free PMC article

Idiosyncratic Quinoline Central Nervous System Toxicity: Historical Insights Into the Chronic Neurological Sequelae of Mefloquine

Remington L Nevin. Int J Parasitol Drugs Drug Resist. .
Free PMC article

Abstract

Mefloquine is a quinoline derivative antimalarial which demonstrates promise for the treatment of schistosomiasis. Traditionally employed in prophylaxis and treatment of chloroquine-resistant Plasmodium falciparum malaria, recent changes to the approved European and U.S. product labeling for mefloquine now warn of a risk of permanent and irreversible neurological sequelae including vertigo, loss of balance and symptoms of polyneuropathy. The newly described permanent nature of certain of these neurological effects challenges the conventional belief that they are due merely to the long half-life of mefloquine and its continued presence in the body, and raises new considerations for the rational use of the drug against parasitic disease. In this opinion, it is proposed that many of the reported lasting adverse neurological effects of mefloquine are consistent with the chronic sequelae of a well characterized but idiosyncratic central nervous system (CNS) toxicity syndrome (or toxidrome) common to certain historical antimalarial and antiparasitic quinolines and associated with a risk of permanent neuronal degeneration within specific CNS regions including the brainstem. Issues in the development and licensing of mefloquine are then considered in the context of historical awareness of the idiosyncratic CNS toxicity of related quinoline drugs. It is anticipated that the information presented in this opinion will aid in the future clinical recognition of the mefloquine toxidrome and its chronic sequelae, and in informing improved regulatory evaluation of mefloquine and related quinoline drugs as they are explored for expanded antiparasitic use and for other indications.

Keywords: Adverse effects; Malaria; Mefloquine; Neurotoxicity; Quinoline; Schistosomiasis.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. Aarnoudse A.L.H.J., van Schaik R.H.N., Dieleman J., Molokhia M., van Riemsdijk M.M., Ligthelm R.J., Overbosch D., van der Heiden I.P., Stricker B.H.C. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther. 2006;80:367–374. - PubMed
    1. Ainley A.D., King H. Antiplasmodial action and chemical constitution. Part II. Some simple synthetic analogues of quinine and cinchonine. Proc. R. Soc. London. Ser. B, Biol. Sci. 1938;125:60–92.
    1. Alving A.S., Craige B., Jr., Pullman T.N., Whorton C.M., Jones R., Jr., Eichelberger L. Procedures used at Stateville penitentiary for the testing of potential antimalarial agents. J. Clin. Invest. 1948;27:2–5. - PMC - PubMed
    1. Arasaki K., Nakanishi T. Selective neurotoxicity of clioquinol on the function of the posterior column nuclei. Neurosci. Lett. 1989;107:85–88. - PubMed
    1. Arznei-Telegramm CNS-toxic mefloquine (Lariam) still justified as a malaria medication? Arznei-Telegramm. 2013;44:72.

LinkOut - more resources

Feedback